[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR112019001134A2 - uso de lactama e composição farmacêutica - Google Patents

uso de lactama e composição farmacêutica

Info

Publication number
BR112019001134A2
BR112019001134A2 BR112019001134-0A BR112019001134A BR112019001134A2 BR 112019001134 A2 BR112019001134 A2 BR 112019001134A2 BR 112019001134 A BR112019001134 A BR 112019001134A BR 112019001134 A2 BR112019001134 A2 BR 112019001134A2
Authority
BR
Brazil
Prior art keywords
lactam
pharmaceutical composition
infections
lactams
patients
Prior art date
Application number
BR112019001134-0A
Other languages
English (en)
Inventor
James Parry Neil
Pantalone Paolo
Williams Paul
Original Assignee
Unilever N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unilever N.V. filed Critical Unilever N.V.
Publication of BR112019001134A2 publication Critical patent/BR112019001134A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/333—Radicals substituted by oxygen or sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

lactamas para uso no tratamento de infecções do trato respiratório, incluindo infecções pulmonares crônicas em pacientes que têm fibrose cística.
BR112019001134-0A 2016-07-21 2017-07-13 uso de lactama e composição farmacêutica BR112019001134A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16180612 2016-07-21
EP16180612.0 2016-07-21
PCT/EP2017/067782 WO2018015279A1 (en) 2016-07-21 2017-07-13 Lactams for the treatment of respiratory tract infections

Publications (1)

Publication Number Publication Date
BR112019001134A2 true BR112019001134A2 (pt) 2019-04-30

Family

ID=56507483

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019001134-0A BR112019001134A2 (pt) 2016-07-21 2017-07-13 uso de lactama e composição farmacêutica

Country Status (5)

Country Link
US (1) US10875830B2 (pt)
EP (1) EP3487494A1 (pt)
CN (1) CN109475526A (pt)
BR (1) BR112019001134A2 (pt)
WO (1) WO2018015279A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3487495A1 (en) 2016-07-21 2019-05-29 Unilever PLC Lactams for use in the treatment of skin lesions
EP3487494A1 (en) 2016-07-21 2019-05-29 Unilever PLC Lactams for the treatment of respiratory tract infections
WO2018015280A1 (en) 2016-07-21 2018-01-25 Unilever Plc 4-(4-chlorophenyl)-5-methylene-pyrrol-2-one and 5-methylene-4-(p-tolyl)pyrrol-2-one for use in the treatment of gram negative bacterial infections

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2059965A1 (en) 1969-08-06 1971-06-11 Roussel Uclaf Antibacterial gamma-lactam of a 7-p-amino-ph
US3905965A (en) 1969-10-17 1975-09-16 Roussel Uclaf Process of total synthesis of cephalosporin derivatives and intermediates
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
TW383308B (en) 1993-08-24 2000-03-01 Hoffmann La Roche 2-beta-alkenyl penam sulfones as beta-lactamase inhibitors
AU2001258677A1 (en) 2000-05-22 2001-12-03 Dr. Reddy's Research Foundation Novel compounds having antiinflammatory activity: process for their preparation and pharmaceutical compositions containing them
AU2002950862A0 (en) * 2002-08-19 2002-09-12 Biosignal Pty Ltd Furanone derivatives and methods of making same
EP1603874B1 (en) 2003-03-03 2008-05-07 Laboratoires Serono SA G-lactam derivatives as prostaglandin agonists
RU2008134473A (ru) * 2006-01-24 2010-02-27 Байосигнал Лимитед (Au) Новые лактамы
CN101646664B (zh) 2006-10-06 2013-12-04 拜欧希格诺有限公司 呋喃酮化合物
WO2009094807A1 (en) 2008-01-28 2009-08-06 Simpson Biotech Co., Ltd. Compounds from mycelium of antrodia cinnamomea and use thereof
US20110152243A1 (en) 2009-12-23 2011-06-23 Abbott Laboratories Novel thienopyrrole compounds
DE212014000038U1 (de) 2013-02-01 2015-09-21 Unilever N.V. Zusammensetzung
WO2014183164A1 (en) 2013-05-17 2014-11-20 Naresh Kumar Dihydropyrrolones and their use as antimicrobial agents
EP3487494A1 (en) 2016-07-21 2019-05-29 Unilever PLC Lactams for the treatment of respiratory tract infections
WO2018015280A1 (en) 2016-07-21 2018-01-25 Unilever Plc 4-(4-chlorophenyl)-5-methylene-pyrrol-2-one and 5-methylene-4-(p-tolyl)pyrrol-2-one for use in the treatment of gram negative bacterial infections
EP3487495A1 (en) 2016-07-21 2019-05-29 Unilever PLC Lactams for use in the treatment of skin lesions

Also Published As

Publication number Publication date
EP3487494A1 (en) 2019-05-29
WO2018015279A1 (en) 2018-01-25
US10875830B2 (en) 2020-12-29
CN109475526A (zh) 2019-03-15
US20190300479A1 (en) 2019-10-03

Similar Documents

Publication Publication Date Title
MX2024009339A (es) Biomarcadores utiles en el diagnostico de infecciones bacterianas y virales.
BR112015024411A2 (pt) desaza-purinonas macrocíclicas para o tratamento de infeções virais
CA2902714C (en) Bone screws and methods of use thereof
MX2018002723A (es) Macrociclicos peptidomimeticos y usos de los mismos.
BR112015011036A2 (pt) derivados de 2-amino-quinazolina substituídos heterocíclicos para o tratamento de infecções virais
CL2015002733A1 (es) Composición farmacéutica de clorhidrato de s-cetamina.
PH12018502109A1 (en) Medicine obtained by combining fxr agonist and arb
PE20180260A1 (es) Metodos y kits para tratar la depresion
MX2023000796A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
PL3556377T3 (pl) Dalargin do stosowania w leczeniu ostrych infekcji wirusowych dróg oddechowych
IL267344A (en) Pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy
CY1123366T1 (el) Παραγωγα 8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δeκανιου
BR112015029367A2 (pt) terapia combinada compreendendo oxazolidinona-quinolonas para uso no tratamento de infecções bacterianas
BR112017014361A2 (pt) métodos para aperfeiçoamento de terapia celular
BR112017026061A2 (pt) composto, uso de um composto, e, método de tratamento de uma infecção viral
IL267503A (en) Pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy
CY1125014T1 (el) Υποκατεστημενα παραγωγα ξανθινης
CY1122923T1 (el) Παραγωγα 3-((ετερο-)αρυλ)-8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δεκανιου
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
ECSP18060820A (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano
BR112017005828A2 (pt) métodos para tratar ou prevenir uma infecção respiratória, copd e uma exacerbação de copd e para selecionar um inibidor de sinalização notch 3 e/ou notch4, usp de um inibidor de sinalização de notch 3 e/ou notch 4, inibidor de sinalização de notch 3 e/ou notch 4, e, composição farmacêutica.
EA201890614A1 (ru) Комбинированная антибактериальная композиция и короткий курс антибактериальной терапии
BR112019001134A2 (pt) uso de lactama e composição farmacêutica
CL2019001550A1 (es) Fenytoina tópica para uso en el tratamiento del dolor neuropático periférico.
UA118474C2 (uk) (s)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: UNILEVER IP HOLDINGS B.V. (PB)

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]